Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Cancer Research

• Publication date

  2012-10-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-2715PMID 23052253PMCID PMC3525716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression

  2012cited by this paper
• Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer

  2012cited by this paper
• Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity.

  2011cited by this paper
• Systemic anti-tumor activity of liposomal glucocorticoids.

  2011influential reference
• RNA interference in the clinic: challenges and future directions

  2011cited by this paper
• Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4.

  2011cited by this paper
• Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody

  2010cited by this paper
• Nanomedicine based approaches for the delivery of siRNA in cancer

  2010cited by this paper
• Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

  2010cited by this paper
• Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

  2009cited by this paper
• TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation

  2008cited by this paper
• Role of the TMPRSS2-ERG gene fusion in prostate cancer.

  2008cited by this paper
• Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.

  2008influential reference
• Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.

  2008cited by this paper
• Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers

  2007cited by this paper
• Potential therapeutic applications of autophagy

  2007cited by this paper
• Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.

  2007cited by this paper
• Diversity of TMPRSS2-ERG fusion transcripts in the human prostate

  2007cited by this paper
• Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.

  2006cited by this paper
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

  2006cited by this paper
• Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.

  2006cited by this paper
• Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy

  2006cited by this paper
• Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

  2005cited by this paper
• NF‐κB activation in human prostate cancer: Important mediator or epiphenomenon?

  2004cited by this paper
• Unlocking the potential of the human genome with RNA interference

  2004cited by this paper
• The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis

  2004cited by this paper
• The Expression of Sprouty1, an Inhibitor of Fibroblast Growth Factor Signal Transduction, Is Decreased in Human Prostate Cancer

  2004cited by this paper
• NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?

  2004cited by this paper
• Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.

  2003cited by this paper
• Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

  2002cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001cited by this paper
• Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.

  1999cited by this paper

• Unveiling the Interaction Mechanism of siRNA with Lipid Bilayers of Different Types for siRNA-Based Therapy.

  2025cites this paper
• Hepatotoxicity of Nanoparticle-Based Anti-Cancer Drugs: Insights into Toxicity and Mitigation Strategies

  2025cites this paper
• The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer

  2025cites this paper
• Targeting and engineering biomarkers for prostate cancer therapy.

  2025cites this paper
• Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours

  2023cites this paper
• Handheld ISFET Lab-on-Chip Detection of TMPRSS2-ERG and AR mRNA for Prostate Cancer Prognostics

  2023cites this paper
• Aptamers in neuro-oncology: An emerging therapeutic modality

  2023cites this paper
• Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer

  2022cites this paper
• ETS factors in prostate cancer.

  2022cites this paper
• The roles of ETS transcription factors in liver fibrosis

  2022cites this paper
• Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA

  2022cites this paper
• Biopolymer Matrix Composite for Drug Delivery Applications in Cancer

  2021cites this paper
• ETS transcription factors as emerging drug targets in cancer

  2020cites this paper
• Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer

  2019influential citation
• Oncogenic ETS Factors in Prostate Cancer.

  2019cites this paper
• ChiTaRS 5.0: the comprehensive database of chimeric transcripts matched with druggable fusions and 3D chromatin maps

  2019cites this paper
• The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target.

  2019cites this paper
• High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases

  2018cites this paper
• Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

  2018cites this paper
• Gene Expression Analysis

  2018cites this paper
• The role of the ETS factor ELF3 in the normal and malignant prostate

  2018cites this paper
• Overcoming Temozolomide Resistance in Glioblastoma Multiforme with MGMT-Targeting Spherical Nucleic Acids

  2017cites this paper
• Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer

  2017cites this paper
• Advances on nucleic acid delivery with nonviral vectors

  2017cites this paper
• Stem cells and the role of ETS transcription factors in the differentiation hierarchy of normal and malignant prostate epithelium.

  2017cites this paper
• Emerging aspects of microRNA interaction with TMPRSS2-ERG and endocrine therapy.

  2017cites this paper
• The ETS family of oncogenic transcription factors in solid tumours

  2017cites this paper
• Lipid nanoparticles as non-viral vectors for siRNA delivery

  2016cites this paper
• TMPRSS2-ERG fusion promotes prostate cancer metastases in bone

  2016cites this paper
• Drug discovery in advanced prostate cancer: translating biology into therapy

  2016cites this paper
• The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker

  2016cites this paper
• The oncogene ERG: a key factor in prostate cancer

  2016cites this paper
• Fusion Genes and their Detection through Next Generation Sequencing in Malignant Hematological Disease and Solid Tumors

  2016cites this paper
• Expression of ERG protein in prostate cancer: variability and biological correlates.

  2015cites this paper
• STAMP2 increases oxidative stress and is critical for prostate cancer

  2015cites this paper
• Nanoparticle Conjugates for Small Interfering RNA Delivery

  2015cites this paper
• Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence

  2015cites this paper
• Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.

  2015cites this paper
• Preclinical and clinical development of siRNA-based therapeutics.

  2015cites this paper
• Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer

  2015cites this paper
• Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis

  2015cites this paper
• FGF23 promotes prostate cancer progression

  2015cites this paper
• TMPRSS2-ERG gene fusion in prostate cancer.

  2014cites this paper
• Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth

  2014cites this paper
• Liposomal nanomedicines in the treatment of prostate cancer.

  2014cites this paper
• Tmprss2-Erg Regulation Of Androgen Biosynthetic Enzyme Expression, Dht Synthesis, And Androgen Receptor Activation In Prostate Cancer

  2014cites this paper
• Evaluation of protein biomarkers of prostate cancer aggressiveness

  2014cites this paper
• Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells

  2014cites this paper
• Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer

  2014cites this paper
• Liposomal siRNA nanocarriers for cancer therapy.

  2014cites this paper
• V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application.

  2013cites this paper
• The latest advances of experimental research on targeted gene therapy for prostate cancer

  2013cites this paper
• Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India

  2013cites this paper
• ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.

  2013cites this paper
• Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo

  2013cites this paper
• Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.

  2013cites this paper
• Recurrent Gene Fusions in Prostate Cancer: Their Clinical Implications and Uses

  2013cites this paper